Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
Medpage Today on MSN2d
Which High-Risk Patients Should Get the RSV Vaccine?The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...
The bottom half of the list featured Reckitt Benckiser’s Mucinex, AstraZeneca’s Breztri Aerosphere, Otsuka’s Rexulti, ...
TipRanks on MSN1d
GSK downgraded to Hold from Buy at JefferiesJefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...
AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback